The spectrum of cutaneous eruptions associated with dihydropyridines is extensive, varying from exanthemas to severe adverse events. We report a case of bullous eruption, one month after starting nicardipine and lercanidipine. The same symptoms recurred few days after taking nitrendipine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2515/therapie/2015023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary Cancers.
Cancers (Basel)
January 2025
Division of Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
The landscape of available therapeutic options for treatment of genitourinary (GU) cancers is expanding dramatically. Many of these treatments have distinct, sometimes severe, skin toxicities including morbilliform, bullous, pustular, lichenoid, eczematous, psoriasiform, and palmoplantar eruptions. Pruritus and skin pigmentation changes have also been noted.
View Article and Find Full Text PDFA Rare Case of Prurigo Pigmentosa in Iranian Sibling Couple.
Clin Case Rep
January 2025
Department of Dermatology Razi Hospital, Tehran University of Medical Sciences (TUMS) Tehran Iran.
Prurigo Pigmentosa is a rare inflammatory skin disease of unknown origin, characterized by pruritic, erythematous papules on the chest, back, neck, and anterior abdomen. The eruption resolves with reticular hyperpigmentation that cosmetically affects the patient's quality of life. Previous reports highlighted the role of the Ketogenic diet in triggering the disease in young female patients, however, no study reported the occurrence of Prurigo Pigmentosa in siblings of one family, unrelated to a ketogenic diet.
View Article and Find Full Text PDFRare delayed hypersensitivity reactions to contrast media: Severe cutaneous adverse reactions.
Eur J Radiol
December 2024
Allergy Unit, Allergo-Anaesthesia Unit, Hospital Universitario de la Cruz Roja, Madrid, Spain.
The risk of developing a severe delayed cutaneous reaction (SCAR) is very low following iodine-based contrast medium (ICM) administration and extremely low following gadolinium-based contrast agent (GBCA) administration. However, SCAR can be very severe and potentially life-threatening. It is crucial for the imaging physician to recognize danger signals: bullous skin eruption, skin erosion and detachment, mucosal involvement, systemic symptoms, and laboratory abnormalities.
View Article and Find Full Text PDFNovel Presentation of Lichenoid Dermatoses Preceding Bullous Pemphigoid Secondary to Immune Checkpoint Inhibitor Therapy.
Skinmed
January 2025
Department of Dermatology, Medical Center, Bronx, NY;
The 73-year-old non-Hispanic, African-American man with a history of renal cell carcinoma (RCC), status post-nephrectomy receiving Lenvatinib, and metastatic disease, for which he also had received nivolumab for 13½ months. An itchy eruption appeared one month after the discontinuation of nivolumab and after the beginning of axitinib therapy. Physical examination revealed pink-violaceous scaly plaques, some with trailing scales on the anterior aspect of the trunk (Figure 1), a slight erosion on the hard palate, and hypopigmentation on the hands and legs.
View Article and Find Full Text PDFClinical cues for distinguishing bullous fixed drug eruption from Stevens-Johnson syndrome: A case report.
SAGE Open Med Case Rep
December 2024
Department of Dermatology, KCU-GME Consortium/Advanced Dermatology and Cosmetic Surgery, Orlando, FL, USA.
This case report discusses two clinical encounters of a 62-year-old Hispanic woman initially hospitalized with suspected Stevens-Johnson syndrome, later correctly diagnosed with bullous fixed drug eruption during an outpatient visit for a similar eruption. The first encounter involved an extensive evaluation and an 11-day hospital stay, while the second was managed successfully as an outpatient with oral prednisone. This report highlights the importance of differentiating bullous fixed drug eruption from Stevens-Johnson syndrome/toxic epidermal necrolysis and emphasizes the need for a collaborative approach between Primary Care Providers and Dermatology to ensure optimal patient care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!